|
Market Closed -
London S.E.
09:05:17 16/10/2026 pm IST
|
5-day change | 1st Jan Change | ||
| 82.50 GBX | 0.00% |
|
+13.79% | +2.48% |
| 15/10 | Arecor Therapeutics Obtains Patents in Europe, US, India, for Rapid-acting Insulin | MT |
| 15/10 | Arecor Therapeutics Plc Strengthens Patent Protection For Its Proprietary AT278 Product | CI |
| Market Cap | 3.74Cr 4.99Cr 4.43Cr 4.11Cr 7.05Cr 473.18Cr 7.17Cr 49Cr 19Cr 246.93Cr 19Cr 18Cr 787.16Cr | P/E 2026 * |
-
| P/E 2027 * | - |
|---|---|---|---|---|---|
| Enterprise Value | 3.18Cr 4.24Cr 3.77Cr 3.5Cr 6Cr 402.7Cr 6.1Cr 42Cr 16Cr 210.14Cr 16Cr 16Cr 669.9Cr | EV / Sales 2026 * |
106x | EV / Sales 2027 * | 181x |
| Free-Float |
55.19% | Yield 2026 * |
-
| Yield 2027 * | - |
London S.E.GBX
| Markets | Quality | ||
|---|---|---|---|
London S.E.
| AREC | Delayed | |
Deutsche Boerse AG
| 6UI | Delayed | |
|
Börse Stuttgart
| 6UI | Delayed |
Last Transcript: Arecor Therapeutics plc
| 1 week | +13.79% | ||
| Current month | +13.79% | ||
| 1 month | +1.85% | ||
| 3 months | +29.92% | ||
| 6 months | +25.00% | ||
| Current year | +2.48% |
| 1 week | 71 |  | 85 |
| 1 month | 70 | | 90 |
| Current year | 55.27 | | 95 |
| 1 year | 55.27 | | 95 |
| 3 years | 35.4 | | 199 |
| 5 years | 35.4 | | 449 |
| 10 years | 35.4 | | 472 |
| Manager | Title | Age | Since |
|---|---|---|---|
Sarah Howell
CEO | Chief Executive Officer | 51 | 13/04/2021 |
David J. Ellam
DFI | Director of Finance/CFO | - | 18/11/2024 |
Jan Jezek
CTO | Chief Tech/Sci/R&D Officer | - | 01/08/2007 |
| Director | Title | Age | Since |
|---|---|---|---|
Sarah Howell
BRD | Director/Board Member | 51 | 13/04/2021 |
Mohammad Fazeli
BRD | Director/Board Member | 61 | 01/09/2017 |
Andrew Richards
CHM | Chairman | 66 | 13/04/2021 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 20/05/26 | Free | Chief Executive Officer | 1,60,000 | 0.4238% | ||
| 20/05/26 | Free | Executive/Senior Manager | 95,000 | 0.2516% | ||
| 20/05/26 | Free | Chief Financial Officer | 1,05,000 | 0.2781% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 0.00% | +13.79% | +6.45% | -57.14% | 4.95Cr | |
| -6.60% | -10.93% | +45.08% | +60.01% | 6.9TCr | |
| -4.09% | +3.12% | +3.71% | +53.50% | 5.31TCr | |
| +0.03% | +7.21% | +12.52% | +44.46% | 5.08TCr | |
| -1.53% | +2.70% | +29.72% | +34.13% | 4.46TCr | |
| -5.97% | -6.22% | +258.21% | +421.57% | 4.06TCr | |
| -1.34% | +4.12% | +16.05% | +112.18% | 4.25TCr | |
| +6.53% | +8.02% | +18.98% | +54.58% | 3.09TCr | |
| -0.90% | -10.91% | +34.11% | -1.83% | 2.54TCr | |
| -2.76% | -9.54% | -16.53% | -9.55% | 2.27TCr | |
| Average | -1.69% | +2.75% | +40.83% | +71.19% | 3.8TCr | |
| Weighted average by Cap. | -2.47% | +1.66% | +46.10% | +89.69% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 3L 4L 4L 3L 6L 3.8Cr 6L 39.63L 15.54L 1.98Cr 15.02L 14.7L 6.32Cr | 2L 3L 2L 2L 4L 2.6Cr 4L 27.08L 10.62L 1.35Cr 10.26L 10.05L 4.32Cr |
| Net income | - | - |
| Net Debt | -55.67L -74.27L -66.02L -61.19L -1.05Cr -70Cr -1.07Cr -7.36Cr -2.88Cr -37Cr -2.79Cr -2.73Cr -117.26Cr | -2L -3L -3L -3L -5L -3.15Cr -5L -32.87L -12.89L -1.64Cr -12.46L -12.19L -5.24Cr |
Employees
33
| Date | Price | Change | Volume |
|---|---|---|---|
| 16/26/16 | GBX 82.50 | 0.00% | 83,875 |
| 15/26/15 | GBX 82.50 | +3.12% | 48,629 |
| 14/26/14 | GBX 80.00 | +6.67% | 19,113 |
| 13/26/13 | GBX 75.00 | 0.00% | 11,505 |
| 12/26/12 | GBX 75.00 | +3.45% | 58,831 |
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
0.8250GBP
Average target price
2.505GBP
Spread / Average Target
+203.64%
Annual profits - Rate of surprise
- Stock Market
- Stocks
- AREC Stock
Select your edition
All financial news and data tailored to specific country editions
